<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45308">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02018926</url>
  </required_header>
  <id_info>
    <org_study_id>0103-014</org_study_id>
    <nct_id>NCT02018926</nct_id>
  </id_info>
  <brief_title>Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS</brief_title>
  <official_title>A Phase I, Multi-Center, Single-Arm, Open-Label Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MethylGene Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MethylGene Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mocetinostat is an orally administered histone deacetylase (HDAC) inhibitor.  Azacitidine is
      a hypomethylating agent (HMA) used to treat MDS.  In this study, patients with intermediate-
      or high-risk MDS will receive treatment with mocetinostat and azacitidine to evaluate the
      safety of the study treatment.  Safety assessments will include echocardiograms,
      electrocardiograms and routine safety laboratory studies (hematology and serum chemistry).
      In addition, clinical response to treatment will be monitored using bone marrow aspirates or
      biopsies, and other routine methods.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of subjects with adverse events, including pericardial events, as a measure of safety</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects experiencing clinical disease response</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Mocetinostat and azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Mocetinostat (MGCD0103) Mocetinostat (a histone deacetylase [HDAC] inhibitor) 70 mg dose, oral capsules 3 times weekly beginning on day 5 for 10 doses in each 28 day cycle
Drug: Azacitidine (Vidaza) Azacitidine (a hypomethylating agent [HMA]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mocetinostat</intervention_name>
    <description>Mocetinostat (a histone deacetylase [HDAC] inhibitor) 70 mg dose, oral capsules 3 times weekly beginning on day 5, for 10 doses in each 28 day cycle</description>
    <arm_group_label>Mocetinostat and azacitidine</arm_group_label>
    <other_name>MGCD0103</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine (a hypomethylating agent [HMA]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle</description>
    <arm_group_label>Mocetinostat and azacitidine</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Diagnosis of intermediate- or high-risk (IPSS criteria) myelodysplastic syndrome.

        Any prior treatment, including no prior treatment. ECOG Performance Status 0 or 1.

        Exclusion Criteria:

        Current or history of small, moderate or large pericardial effusion, tamponade and/or
        pericarditis.

        Significant cardiac abnormalities such as recent myocardial infarction, congestive heart
        failure â‰¥ Class 3, or symptomatic, uncontrolled atrial fibrillation, atrial flutter or
        sinus tachycardia.

        Prolonged QT/QTc interval.

        Other active cancer excluding basal cell carcinoma or cervical intraepithelial neoplasia.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Chao, MD</last_name>
    <role>Study Director</role>
    <affiliation>MethylGene Inc./Mirati Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Collier</last_name>
    <phone>858-332-3410</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care and Vermont Cancer Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 14, 2014</lastchanged_date>
  <firstreceived_date>December 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mocetinostat</keyword>
  <keyword>Azacitidine</keyword>
  <keyword>Vidaza</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>HDAC</keyword>
  <keyword>HMA</keyword>
  <keyword>MDS</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>N-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
